INDEX

Accelerated extraction
  accelerated aging, 170
definition of, 33
eexample of, 40
  use in classification of substances, 9
  use in simulation study, 162
  versus exaggerated extraction, 34, 40, 162
Analysis of extracts
  bibliography of methods for, 139
discovery, 127
  identification, 128
  in compendia testing, 99
  in controlled extraction study, 334
  in simulation study, 171
  process of, 124
  scouting, 125
Analytical Evaluation Threshold (AET)
  application of in simulation study, 181
  definition of, 181
  in controlled extraction study, 335
  uncertainty in, 183
Analytical methods
  best demonstrated practices, 334
  bibliography, 139
  for identification, 51
  in extractables assessment, 124, 126
  use in simulation study, 171
  validation of, 196, 214
Bad actors, 53
  and AET, 182
  discovery of, 183
  for OINDP, 336
Best demonstrated practices
  analytical methods, 334
  controlled extraction study, 333
  data mining, 332
  general guidelines for E&L studies, 331
  PQRI, 331
  thresholds, 335
Binding, see Sorption
- as part of compatibility assessment, 5
- definition, 3
- relationship to leaching, 4
- suitability for use, 338

Biological assessment
- applicable tests, 60, 62
- classification of devices, 59
- classification of plastics, 60, 61
- use in safety assessment, 23
- USP <87>, 21, 100
- USP <88>, 21, 100

Biopharmaceuticals
- case studies
  - bioprocessing materials, 327
  - bulk drug substance, 326
  - containers, 174
  - filter cartridge, 138
  - tubing materials, 131
- effects of extractables and leachables on, 338
- manufacturing systems for, 136, 138, 174

BioProcess Systems Alliance (BPSA)
- examples of plastic disposables, 320
- plastic systems qualification, 322
- process flow diagram, 323
- recommendations, 324

Change control
- as a leachables test, 274
- case study, 297
- comparability protocol for, 284
- differential versus direct approach, 288
- evaluation recommendation, 295
- examples of, 283
- experimental assessment, 288
- impact assessment, 285
- preliminary assessment, 286
- regulatory reporting strategies, 284
- stages in, 285
- steps in, 290, 291

Common Technical Document (CTD)
- for regulatory submissions, 251
- Section 3.2.P.7, Description, 252
- Section 3.2.P.2.4, Suitability, 254
- compendial compliance, 254
- extraction study, 255
- migration study, 258
- toxicological assessment, 261

Compatibility
- assessment of, 4, 146
- dimensions of, 5
- FDA container closure guidance, 337
- potential interactions, 338

Comparability Protocol
- FDA Draft Guidance for, 284
- use in change control, 284

Compendial testing
- compliance testing, 23, 105, 146, 259
- EP 3.0 series, 102
- JP 7.0 series, 101
- in registration dossier, 254
- role in safety assessment, 103
- tests and test methods, 99
- USP <87>, see Biological assessment
- USP <88>, see Biological assessment
- USP <381>, 97
- USP <661>, 98

Construct
- combination, 29
- definition of, 7
- delivery, 29
- examples of, 8
- manufacturing, 28
- materials used in, 348
- packaging, 29
- types of additives in, 349

Construct qualification
- early development stage, 191
- input output diagram, 86
- position in the product life cycle, 79
- prototype stage, 159
INDEX 373

Construct validation
input output diagram, 86
late stage product development, 231
launch, 265
position in the product life cycle, 79, 80
submission, 249

Container closure system
definition of, per FDA, 15
description of, in the registration dossier, 253

Contract Research Organization, CRO, choice of, 340

Controlled extraction study, 332
recommendations for, 333

Correlation of extractables and leachables
decision tree, 48
desirable outcomes, 43
examples of
DEHP and related substances, 46
Irgafos 168 and related substances, 303
Irganox 1076 and related substances, 12
hierarchy for, 45
requirements for, 48
target leachables, 49

Disaster management
class A disaster, unusual change in leachable concentration, 239
description of, 239

relationship to out-of-limits investigation, 240
class B disaster, previously unobserved leachables, 241
during product maintenance, 305
atypical product, 305
change in regulations, 312
product use (in the field) issues, 309

Discovery of extractables
analytical methods for, 126, 131
discussion of, 127
purpose of, 124
role of reconciliation in, 140

Dissolution
definition of, 34, 39
desirable outcomes, 43
examples of
DEHP and related substances, 46
Irgafos 168 and related substances, 303
Irganox 1076 and related substances, 12
hierarchy for, 45
requirements for, 48

target leachables, 49

Early development stage
goals, objectives, purpose, 191
method development, evaluation and validation, 194
place in the product life cycle, 78, 81
target leachables, 192

Extractables Leachables Safety Information Exchange (ELSIE), 344

EMEA Guidelines on Plastic Immediate Packaging Materials
decision tree for required testing, 19
requirements for extractions, 117
Section 3.2 Specifications, 16, 254
Section 4.0 Extraction Studies, 16, 117
Section 5.0 Interaction Studies, 17
Section 5.1 Migration Studies, 17, 233
Section 6.0 Toxicological Information, 18
test matrix, 66

Difference study, see also, Change control
case study, 297
definition of, 288
in change control, 288
steps in, 290, 291

Disaster management
class A disaster, unusual change in leachable concentration, 239
description of, 239
Elastomers, case studies, 136, 137, 225
Emerging concepts
  best demonstrated practices, 331
  general guidelines for E&L studies, 331
  controlled extraction study, 333
CRO, choice of, 340
manufacturing systems, 320
  BPSA, 322
case studies, 138, 174, 327
examples of, 320
industry recommendations, 322
leachables versus impurities, 328
process flow diagram, 323, 327
recommendations for testing of, 324
regulatory requirements, 321
risk evaluation for, 71 73
suitability for use, 337
EPREX®, 4, 339
Exaggerated extraction
definition of, 34, 35
example of, 40
use for determining total pool, 143
use in classification of substances, 9
use in simulation study, 162
versus accelerated extraction, 34, 40, 162
Extractables
  comparison to leachables, 9, 11
correlation to leachables, 43
definition of, 8, 31
description of, in the registration dossier, 258
identification of, 50, 51, 124, 128
in ongoing quality control (QC), 274
relationship to leachables, 151
relationship to ingredients, 10
Extractables survey
  case studies, 131, 136, 137, 138, 297
components of, 146
definition of, 112
desired outcome, 112
extract analysis and, 124
ideal extraction process, 115
intent and purposes of, 113
primary directives for extractions, 116
total available pool, 142
total pool, 142
use of fully processed materials for, 121
Extraction
  accelerated, 34, 35, 40
  aggressive, 34, 35, 40
  controlled, 332
definition, 32
exaggerated, 34, 35, 40
exhaustive, 34, 36, 40
examples of, 35, 40
for simulation study, 162
for material characterization, 112
passive versus aggressive, 118
primary directives for, 116
regulatory guidance for, 116
strategies, 32, 34
10% rule, 38, 145
Extraction study, see also, material characterization
controlled extraction study, 332
general, 24
input output diagram, 86
relationship to product life cycle, 79
Extracting media
  case studies, 121, 172, 174
drug product as, 31
drug product vehicle, 31
effect on extractables profile, 121, 122, 123
in compendial testing, 99
in controlled extraction studies, 332
placebo, 32, 168
process of minimization, 167
INDEX

simulating solvent, 31
simulating the therapeutic product, 166

FDA Draft Guidance for Industry, Comparability Protocols
in change control, 284
reference for, 313

FDA Guidance for Industry, Container Closure Systems
extracting media, 117
general outline of, 4
migration study, 234
packaging concerns, 64
reference for, 26
requirements for extraction, 118
risk categories, 58
suitability for use considerations, 14, 65, 337

FDA Guidance for Industry: Metered Dose Inhaler (MDI) and Dry Powder (DPI) Drug Products
correlation of extractables and leachables, 93
general outline of, 19
migration study, 234
reference for, 26

FDA Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension and Spray Drug Products
general outline, 19
reference for, 26

Historical extractables and leachables file, contents of, 316
use in product retirement, 315

Identification
analytical methods for, 51, 126, 131
discussion of, 128
levels of, 50, 51
purpose, 124
required information, 53

ISO 10993 Series, Device assessment
10993:1 Selection of Tests, 20, 60
categorization of devices, 59
10993:12 Sample Preparation, 20
10993:17 Allowable Limits, 20, 185
10993:18 Chemical Characterization, 20, 152
categorization of medical devices, 20
references for, 26
tests in, 60
toxicological equivalency, 304

Late stage product development
disaster management, 238
migration study, 231
objectives of, 80, 231
place in product life cycle, 78, 81
product stability issues, 244
Launch
position in the product life cycle, 79, 81
response to dossier review questions, 265

Leachables
comparison to extractables, 9, 12
correlation to extractables, 43
definition of, 8, 31
impact on product stability, 242
impact on active ingredient and impurity assays, 242
in change control, 274
migration study, 231
quantitation of, see Quantitation relationship to extractables, 151
target leachables, 192

Manufacturing systems, see also BPSA
extractables and leachables assessment for, 323
filters, 138
Manufacturing systems (cont’d)
  process containers, 174
  risk classification of, 71, 73
  tubing, 131
Master flow diagram
  discussion of, 78
  input output diagram, 86
  outline of, 79
Material characterization
  components of, 92
  device perspective, 152
  extractables survey for, 112
  input output diagram, 86
  objectives of, 103
  process map, 93
  position in the product lifecycle, 79
  versus material screening, 94
  via collection of vendor information, 104
Material screening
  input output diagram, 86
  phase in the product life cycle, 78
  process map, 93
  purpose of, 93
  versus material characterization, 94
Method development (optimization)
  conducting method development, 200
  overview, 198
  performance assessment, 201, 204
  prerequisites for, 195
  process diagram, 196
  role of screening methods, 195
  troubleshooting, 202
Method evaluation
  accuracy, 209
  aspects of, 208
  intermediate precision, 213
  linearity, 211
  overview of, 208
  precision, 210
  primary analyst, 209
  process diagram, 196
  secondary analyst, 213
  solution stability, 212
  specificity, 210
  template for, 209
Method validation
  acceptance criteria, 215, 219
  case studies, 215, 225
  for migration studies, 236
  process diagram, 196
  USP <1225>, 207
Migration study
  design of
    EMEA guidelines, 233
    FDA Guidance, 233
    optimal, 234
  dimensions of, 236
  general requirements, 24
  interpretation of (toxicological assessment), 238
  relationship to product life cycle, 78, 81, 231
Nomenclature
  classification of entities in constructs, 30, 31
  constructs, 28
  correlation of extractables and leachables, 43
  definition of extractables and leachables, 8, 31
  extractable versus ingredient, 10
  extracting media, 31
  extraction categories, 32, 34, 40
  identification categories for extractables and leachables, 50
  leachable versus process impurity, 328
  risk categories, 58
Product life cycle
  construct qualification, 157
  construct validation, 229
  material characterization, 89
  overview of, 78, 79
  product maintenance, 271
Product maintenance
change control, 282
changes in regulations, 312
disaster management, 305
input output diagram, 86
ongoing quality control, 275
position in the product lifecycle, 79
retirement, 315
toxicological equivalence, 304
value improvement programs (VIP), 273, 296
Product Quality Research Institute (PQRI), 331, see also, Best demonstrated practices
inhaled products, 343
parenteral products (PODP), 343
thresholds, 335
Product retirement
input output diagram, 86
phase in the product life cycle, 82
historical extractables and leachables file, 316
Prototype stage
activities in, 160
as an insurance policy, 160
input output diagram, 86
place in the product life cycle, 78, 81
simulation study, 161
toxicological assessment in, 184
Qualification threshold (QT)
definition of, 55
value of, for OINDP, 55
use in risk assessment, 56
Quality control
acceptance criteria in, 282
as an extractables test, 274
associated costs, 277
major issues in, 276
of finished goods, 279
of incoming raw materials, 275
of in-process goods, 278
specifications for, 281
Quantitation
accuracy in, 219
analytical methods for, 126, 133
development, evaluation and validation of methods for, see Analytical methods
for extractables profile, 125
in simulation study, 171
purpose of, 124, 128
Regulatory Guidance, see
EMEA Guidelines in Plastic Immediate Packaging Materials
FDA Guidance for Industry, Container Closure Systems
FDA Guidance for Industry, Metered Dose Inhaler (MDI) and Dry Powder (DPI) Drug Products
FDA Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension and Spray Drug Products
FDA Draft Guidance for Industry, Comparability Protocols
for manufacturing systems, 321
Retirement
historical extractables and leachables file, 316
place in the product life cycle, 78, 81
Risk
classification of
ASTM F748-06, 62
FDA Container Closure Guidance, 64
for manufacturing systems, 71, 322
ISO 10993-1 classification of devices, 59, 60
USP <88>, 61
USP <1031>, 60
Risk (cont’d)
management of
in extractables survey, 118
in toxicological assessment, 184
nature of contact risk
assessment maps, 67
risk evaluation for manufacturing
systems, 73, 322
use of thresholds in, 55, 181

Safety assessment, see Toxicological
assessment
Safety Concern Threshold (SCT)
definition of, 55
relationship to AET, 182
use in risk management, 56
value for OINDP, 55

Scouting for extractables,
analytical methods for, 126
case study, 132
discussion of, 125
purpose of, 124

Simulation
accelerated aging, 170
case studies, 164, 172
of contact parameters, 164
of exposure parameters, 169
of the therapeutic product, 166
minimization process, in, 167
parameters to simulate, 164

Simulating solvents
best demonstrated practices, 384
elements of, 40
for biopharmaceutical solutions, 175
for solubilizing agents, 172
in material screening, 121
minimization process for
identifying, 167
types of, 31
use of, 31

Simulation study
extractions for, 162
extract analysis in, 171
phase in the product lifecycle, 80
preliminary toxicological
assessment, 184
process of, 162
purpose of, 161

Sorption, see also, Binding,
Suitability for use
definition of, 3
relationship to leaching, 4
as a suitability for use parameter, 337

Submission
dossier format, 251, see also
Common Technical Document
position in the product life cycle, 79, 81
questions arising from, 266

Suitability for use, see also
Compatibility
considerations for common
classes of drug products
(FDA), 65
dimensions of, 5, 337
EPREX®, 339
FDA Container Closure
Guidance, 337
potential interactions, 338

Suppliers as a source of extractables
information
best demonstrated practices (data
mining), 332
material questionnaire, 105
process flow diagrams for
interactions with suppliers, 111
roles and responsibilities in, 110

System suitability
elements of, 224
in method evaluation, 214
in the regulatory dossier, 257
parameters for, 205
purpose of, 205

Target leachables,
application of, in migration study, 233
criteria for, 193
definition of, 192
during product development, 86
in change control, 293
Therapeutic substance
definition of, 7
eamples of, 8
stimulants for, 31, 175
Thresholds, see also Analytical Evaluation Threseshold, Safety Concern Threshold, Qualifcation Threshold
application of, 181
definitions of, 55, 181
reporting in the registration dossier, 261
uncertainty in, 183
use in controlled extraction study, 335
Total available pool, 93, 143
Total pool
as the worse case for accumulation, 104
case study, 145
concept of, 142
extractions for, 143
rule of 10%, 38, 145
successive extractions for, 145
Total Organic Carbon (TOC)
case study, 142
reconciliation of, 140
role of, in extractables discovery, 125
use of, in screening, 133
Toxicological assessment
biological testing for, 21
for cyclohexanone, 188
for devices, 152
in migration study, 238
in change control, 291
in simulation study, 80, 184
per ISO 10993:17, 185
placement in the registration dossier, 261
process of, 53, 56, 185
regulatory requirement for, 24
strategies for, 23
total pool, 143
toxicological equivalency, 304
use of extractables data for, 149
Validation of analytical methods
case studies, 215, 225
process for, 196, 214
requirement of, in migration studies, 233, 234